From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|October 14, 2021
Daily Medication Pearl: Maralixibat (Livmarli) for Cholestatic Pruritus
Author(s)Saro Arakelians, PharmD
Maralixibat decreases the reabsorption of bile acids from the terminal ileum for the treatment of cholestatic pruritus in patients with Alagille syndrome.
Advertisement
Clinical Pearl of the Day: Maralixibat (Livmarli)
Maralixibat is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Insight:
- Dosage: The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day. Starting dose is 190 mcg/kg orally once daily and should be increased to 380 mcg/kg once daily after 1 week, as tolerated.
- Dosing: Oral solution 9.5 mg of maralixibat per mL.
- Adverse events: Include diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
- Mechanism of action: Maralixibat decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
- Manufacturer: Mirum
Sources:
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5